Quanta Services Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Quanta Services Inc trades at $643.13 (market cap $95.92B), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: Quanta Services Inc pays a 0.07% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Quanta Services Inc nearer its low. Which is the better fit depends on your goals.
| PWR | XBI | |
|---|---|---|
Market Cap | $95.92B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $785.24 | $164.28 |
52-Week Low | $372.50 | $85.16 |
Enterprise Value | $101.87B | — |
Dividend Yield | 0.07% | — |
Signals from Pluang's Aura AI — not financial advice
PWR (Quanta Services) trades at $639.20, up 1.7% with strong analyst support (75% buy ratings) and a consensus price target of $836.80. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 3.67%. Recent technical indicators are bearish despite oversold RSI readings, with key support at $613. The company benefits from AI infrastructure demand and utility spending, with a record $48B backlog.
Outlook is positive given exposure to grid modernization and AI data center build-out, but high valuation (P/E 86.77) and execution risks pose challenges. Earnings have consistently beaten estimates, with Q2 2026 results due July 30. Institutional sentiment is bullish, though technical weakness near-term warrants caution.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →